Coya Therapeutics, Inc. (COYA) – What Are Researchers Saying About This Stock?

Coya Therapeutics, Inc. (NASDAQ:COYA) has received a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $15.33.

Several analysts have recently weighed in on COYA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Friday, July 17th. Roth Capital reissued a “buy” rating and set a $12.00 target price on shares of Coya Therapeutics in a research note on Monday, August 24th. HC Wainwright reaffirmed a “buy” rating on shares of Coya Therapeutics in a research note on Friday, September 25th. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Wednesday, August 12th. Finally, BTIG Research reissued a “buy” rating and set a $16.00 price objective on shares of Coya Therapeutics in a research report on Tuesday, September 15th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allworth Financial LP increased its holdings in shares of Coya Therapeutics by 1,200.0% during the second quarter. Allworth Financial LP now owns 13,000 shares of the company’s stock valued at $76,000 after acquiring an additional 12,000 shares in the last quarter. AXQ Capital LP bought a new position in shares of Coya Therapeutics in the 2nd quarter worth $116,000. Long Corridor Asset Management Ltd bought a new position in shares of Coya Therapeutics in the 2nd quarter worth $227,000. ADAR1 Capital Management LLC acquired a new stake in Coya Therapeutics in the 1st quarter valued at $161,000. Finally, Renaissance Technologies LLC increased its stake in Coya Therapeutics by 55.4% during the 1st quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock valued at $410,000 after purchasing an additional 37,064 shares in the last quarter. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Price Performance

Shares of COYA opened at $4.95 on Friday. The business has a 50-day moving average of $4.78 and a 200-day moving average of $4.69. The company has a market capitalization of $116.12 million, a price-to-earnings ratio of -4.63 and a beta of 0.58. Coya Therapeutics has a 1 year low of $3.71 and a 1 year high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. The company had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.13 million. Coya Therapeutics had a negative net margin of 270.22% and a negative return on equity of 52.05%. As a group, sell-side analysts anticipate that Coya Therapeutics will post -1.34 EPS for the current year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies that regulate neuroinflammation and support immune-system function. The company’s research centers on regulatory T cells, or Tregs, immune cells that help control excessive inflammatory responses. Coya is developing treatments intended for neurodegenerative diseases in which inflammation may contribute to disease progression.

The company’s lead programs include COYA 101, an autologous Treg cell therapy in which a patient’s cells are collected, expanded and activated outside the body, and then administered as a potential treatment for amyotrophic lateral sclerosis (ALS).